Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Argenica Therapeutics Ltd ( (AU:AGN) ) has provided an announcement.
Argenica Therapeutics has advanced preparations for a targeted Phase 2b clinical trial of its lead candidate ARG-007 in moderate to severe acute ischaemic stroke, leveraging a precision medicine strategy and AI-enabled diagnostic tools to optimise patient selection and enhance trial efficiency. Manufacturing scale-up with Corden Pharma for late-stage trials and future commercial supply is progressing, de-risking the program, while acceptance of Phase 2 trial data for presentation at a major European stroke conference and a full paediatric waiver from the European Medicines Agency strengthen its European development pathway and global profile.
The company’s financial position was bolstered by a $4.0 million R&D tax refund and additional non-dilutive grant funding, leaving cash reserves of $8.0 million at 31 March 2026 to support Phase 2b trial preparations in consultation with its global stroke advisory group and potential pharmaceutical partners. In parallel, Argenica continues to explore ARG-007’s potential in other neurological conditions, supported by more than $4 million in cumulative grant and philanthropic funding, reinforcing its broader pipeline ambitions and stakeholder interest in its neuroprotective platform.
The most recent analyst rating on (AU:AGN) stock is a Buy with a A$0.64 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.
More about Argenica Therapeutics Ltd
Argenica Therapeutics Limited is an Australian biotechnology company focused on developing novel neuroprotective therapeutics to reduce brain tissue death following stroke and other forms of brain injury. Its lead candidate, ARG-007, targets acute ischaemic stroke patients, with the company positioning itself in the global stroke treatment market through advanced clinical development and partnerships.
Average Trading Volume: 140,605
Technical Sentiment Signal: Sell
Current Market Cap: A$21.84M
For a thorough assessment of AGN stock, go to TipRanks’ Stock Analysis page.